Literature DB >> 25051661

[Pathophysiology, diagnosis and treatment of cough variant asthma].

Masaki Fujimura.   

Abstract

Cough variant asthma (CVA) has been recognized as a precursor of asthma or a pre-asthmatic state because of the mildly heightened bronchial responsiveness and efficacy of bronchodilator therapy. Nevertheless, the accumulating evidence indicates that the pathophysiology is different between CVA and bronchial asthma. The most fundamental physiologic feature is a heightened cough response to methacholine-induced bronchoconstriction in CVA, while this response is rather reduced in bronchial asthma. The sensitivity of cough receptors located in the superficial layer of the airway wall is normal in CVA as well as bronchial asthma, but heightened in atopic cough. The pathologic feature of CVA is eosinophilic inflammation of the central to peripheral airway, reflected by eosinophilia in induced sputum, biopsied bronchial mucosa, and bronchoalveolar lavage fluid. The diagnosis of CVA has been commonly made based on therapeutic diagnostic procedures, while pathophysiologic diagnosis is ideal. The reason is that measurements of the sensitivity of cough receptors to inhaled capsaicin and cough response to induced bronchoconstriction are not possible at most chest clinics in the world. The efficacy of a beta2-agonist for a patient's coughing is evaluated to make a diagnosis of CVA. When the bronchodilator therapy is judged as efficacious, a tentative diagnosis of CVA is made. Then, induction therapy is initiated for resolution of the cough. The induction therapy consists of beta2-agonists, leukotriene receptor antagonists, and inhaled corticosteroids. In some patients whose cough does not subside with the therapy, short-burst oral corticosteroids (1 to 3 weeks) may be added. If the cough still does not subside with the therapy, the patient should be referred to cough specialists. When the cough subsides with the induction therapy, long-term management is recommended using inhaled corticosteroids, because 30% of patients develop typical bronchial asthma within several years. Problems with the therapeutic diagnosis are as follows: spontaneous relief of cough leading to a false positive result, and resistance to the therapy, leading to a false-negative result. Thus, a pathophysiologic diagnostic procedure should be established in the future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25051661

Source DB:  PubMed          Journal:  Rinsho Byori        ISSN: 0047-1860


  8 in total

1.  [Comparison of functional parameters of small airways between patients with typical asthma and cough-variant asthma].

Authors:  Shu-Yu Chen; Ze-Kui Fang; Si Fang; Qi-Xiao Shen; Xi He; Cui-Lan Wang; Hua-Peng Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

2.  Diagnostic Value of Fractional Exhaled Nitric Oxide and Small Airway Function in Differentiating Cough-Variant Asthma from Typical Asthma.

Authors:  Yanqi Wang; Lixuan Zhao; Fang Chen; Yufeng Guo; Hongxia Ma; Baofen Han; Jiang Yi; Xiaomei Kong
Journal:  Can Respir J       Date:  2021-08-20       Impact factor: 2.409

3.  Clinical and pulmonary function changes in cough variant asthma with small airway disease.

Authors:  Honglei Yuan; Xiaojing Liu; Li Li; Gang Wang; Chunfang Liu; Yuzhen Zeng; Ruolin Mao; Chunling Du; Zhihong Chen
Journal:  Allergy Asthma Clin Immunol       Date:  2019-07-02       Impact factor: 3.406

4.  A traditional Chinese patent medicine-Suhuang zhike capsule for cough variant asthma in adults: A protocol of systematic review and meta-analysis of randomized controlled trials.

Authors:  Jianxin Wang; Rui Sun; Ruiyin Wang; Jing Han; Shuhua Zhang; Zetao Yin; Zelu Han; Ying Nong; Jiangtao Lin
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 5.  WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation - Updates in COVID-19.

Authors:  Philip W Rouadi; Samar A Idriss; Jean Bousquet; Tanya M Laidlaw; Cecilio R Azar; Mona S Al-Ahmad; Anahi Yañez; Maryam Ali Y Al-Nesf; Talal M Nsouli; Sami L Bahna; Eliane Abou-Jaoude; Fares H Zaitoun; Usamah M Hadi; Peter W Hellings; Glenis K Scadding; Peter K Smith; Mario Morais-Almeida; René Maximiliano Gómez; Sandra N Gonzalez Diaz; Ludger Klimek; Georges S Juvelekian; Moussa A Riachy; Giorgio Walter Canonica; David Peden; Gary W K Wong; James Sublett; Jonathan A Bernstein; Lianglu Wang; Luciana K Tanno; Manana Chikhladze; Michael Levin; Yoon-Seok Chang; Bryan L Martin; Luis Caraballo; Adnan Custovic; Jose Antonio Ortega-Martell; Erika Jensen-Jarolim; Motohiro Ebisawa; Alessandro Fiocchi; Ignacio J Ansotegui
Journal:  World Allergy Organ J       Date:  2021-11-22       Impact factor: 4.084

6.  Exploration in the Mechanism of Zhisou San for the Treatment of Cough Variant Asthma Based on Network Pharmacology.

Authors:  De-Hai Guo; Jin-Ping Hao; Xing-Jie Li; Qing Miao; Qiong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

7.  Assessment of Acupoint Therapy of Traditional Chinese Medicine on Cough Variant Asthma: A Meta-analysis.

Authors:  Hengjia Tu; Qingling Zhang
Journal:  Biomed Res Int       Date:  2022-07-30       Impact factor: 3.246

8.  Montelukast and budesonide combination for children with chronic cough-variant asthma.

Authors:  Xiu-Ping Wang; Lin-Dong Yang; Jin-Fang Zhou
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.